CAP-100 

CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL^[1].

CAP-100 (0.1-10 ng/μL) demonstrates the most potent binding to CCR7 immunogen SYM1899 (100 ng) with a EC₅₀ of 1.78 ng/mL^[1].
CAP-100 (0.01-100 μg/mL) shows dose-dependent inhibition of ligand-induced activation, reaching maximal inhibitions close to 100% in CCR7⁺ CHO-K1 cells stimulated with CCL19^[1].
CAP-100 (0.1-100 μg/mL) binds to CCR7⁺ non-tumor PB or BM cells from healthy donors at high experimental concentrations^[1].
CAP-100 (1-100 μg/mL) impairs the increase of D-actin upon CCL19/CCL21 stimulation in CLL cells^[1].
CAP-100 (0.1-100 μg/mL, 4 h) demonstrates a strong dose-related inhibitory activity against CCR7-driven T-PLL cells migration towards 1 μg/mL of CCL19 or CCL21^[1].
CAP-100 (10 μg/mL) impairs CCR7-induced migration of CCL cells in trans-endothelial migration (TEM) assays^[1].
CAP-100 (10-100 μg/mL, 24 h) does not mediate direct specific-induced cell death but impairs the viability of CCR7-mediated cells which is the protective function in CLL^[1].
CAP-100 (10 μg/mL) activated human NK-92-CD16⁺ cells to induce a strong ADCC on target CLL cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAP-100 (10 μg/mL, i.v., one single dose) reduces in vivo homing of CCR7-expressing cells to lymph node of NSG mice^[1].
CAP-100 (25-200 μg/mouse, i.v., one single dose) shows prolonged median overall survival regardless of dose and reduces tumor burden as well as reducing lymph node infiltration in Granta-519-luc^{+-bearing mice[1].
CAP-100 (10-200 μg/mouse, i.v., one single dose) significantly extends the lifespan of JVM-3-bearing SCID mice compared to Trastuzumab (HY-P9907) (200 μg)[1].}

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

[CAP-100]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13(1):1917484.  [Content Brief]